ter Medidas cautelares y responsabilidad mancomunada

To date, we have funded our business primarily through inter- nally generated funds, debt, and private and public sales of equity. Our primary use of cash has been to support continuing operations and our investing activities including capital ex- penditure requirements and acquisitions. As of December 31,

2013 and 2012, we had cash and cash equivalents of $ 330.3 million and $ 394.0 million, respectively. We also had short-term investments of $ 49.9 million at December 31, 2013. Cash and cash equivalents are primarily held in U.S. dollars and euros, other than those cash balances maintained in the local currency of subsidiaries to meet local working capital needs. At December 31, 2013, cash and cash equivalents had de- creased by $ 63.7 million from December 31, 2012, primarily as a result of cash used in investing activities of $ 251.7 mil- lion and financing activities of $ 68.8 million partially offset by cash provided by operating activities of $ 259.0 million. As of December 31, 2013 and 2012, we had working capital of $ 583.9 million and $ 725.8 million, respectively.

Operating Activities. For the years ended December 31,

2013 and 2012, we generated net cash from operating activ- ities of $ 259.0 million and $ 244.9 million, respectively. While net income was $ 69.1 million in 2013 non-cash com- ponents in income included $ 199.4 million of depreciation and amortization and $ 42.8 million of impairments primarily due to the discontinuation of development programs. Operating cash flows include a net increase in working capital of $ 5.7 million, primarily due to increased accrued liabilities, including those related to restructuring activities and income tax amounts. Because we rely heavily on cash generated from operating activities to fund our business, a decrease in demand for our products, longer collection cycles or signifi- cant technological advances of competitors would have a negative impact on our liquidity.

Investing Activities. Approximately $ 251.7 million of cash was used in investing activities during 2013, compared to $ 300.9 million during 2012. Investing activities during 2013

consisted principally of $ 20.3 million invested in short-term investments, $ 84.5 million in cash paid for purchases of property and equipment, primarily in our ongoing construction projects in the U.S., as well as $ 34.2 million paid for intangible assets. Cash paid for acquisitions, net of cash acquired, of $ 170.5 million was used primarily in the acquisition of Inge- nuity as discussed in Note 5. As of December 31, 2013, we also had made investments of $ 4.3 million in privately held companies. These investing activities were partially offset by $ 63.1 million from the sale of short-term investments. In 2009 and 2010, we started the expansion of our Hilden, Germany, and Germantown, Maryland, USA, facilities, re- spectively. Both projects were completed at a total cost of $ 97.2 million as of December 31, 2013. There are two addi- tional small expansion projects in Maryland that will be start- ed in 2014 and are estimated to be completed in 2015. We anticipate being able to fund these expansions with cash generated by operating activities.

In connection with certain acquisitions, we could be required to make additional contingent cash payments totaling up to $ 120.3 million based on the achievement of certain revenue

and operating results milestones as follows: $ 65.7 million in

2014, $ 16.5 million in 2015, $ 17.8 million in 2016, $ 7.0 mil- lion in 2017, and $ 13.3 million payable in any 12-month period from now until 2016 based on the accomplishment of certain revenue targets. Of the $ 120.3 million total contingent obli- gation, approximately $ 6.1 million is accrued as of Decem- ber 31, 2013.

Financing Activities. Financing activities used $ 68.8 million in cash for the year ended December 31, 2013 compared to $ 226.6 million provided in 2012. Cash used during 2013 was primarily for the purchase of treasury shares of $ 86.0 million partially offset by $ 25.3 million for the issuance of common shares in connection with our stock plan.

In December 2011, we entered into a € 400.0 million syndi- cated multi-currency revolving credit facility expiring December

2016 of which no amounts were utilized at December 31,

2013. We have additional credit lines totaling € 36.6 million with no expiration date, none of which was utilized as of December 31, 2013. We also have capital lease obligations, including interest, in the aggregate amount of $ 18.3 million, and carry $ 845.5 million of long-term debt, of which $ 0.2 million is current as of December 31, 2013.

We have notes payable, which are the long-term borrowings of the proceeds from the issuances of $ 150.0 million senior unsubordinated convertible notes, with a 1.5 % coupon due in 2024 through QIAGEN Finance (2004 Notes), and of $ 300.0 million 3.25 % senior convertible notes (2006 Notes) due in 2026 through QIAGEN Euro Finance. QIAGEN Finance and Euro Finance are unconsolidated subsidiaries, which were established for this purpose. The 2004 Notes are con- vertible into our common shares at a conversion price of $ 12.6449, subject to adjustment, and the 2006 Notes are convertible into our common shares at a conversion price of $ 20.00, subject to adjustment. In connection with conversion of $ 5.0 million of the 2004 Notes, we repaid $ 5.0 million of the debt to QIAGEN Finance. At December 31, 2013, $ 145.0 million and $ 300.0 million are included in long-term debt for the amount of the notes payable to QIAGEN Fi- nance and Euro Finance, respectively. The $ 145.0 million

C OR POR A TE G O V ER N A NC E ES U LT S

note payable has an effective rate of 1.8 %, and had an original maturity in July 2011. We refinanced the $ 145.0 mil- lion note, which has a new maturity date of February 2024. The $ 300.0 million note payable has an effective rate of

3.7 % and is due in May 2026. QIAGEN N.V. has guaran- teed the 2004 and 2006 Notes and has agreements with

QIAGEN Finance and Euro Finance to issue shares to the in- vestors in the event of conversion. These subscription rights, along with the related receivable, are recorded at fair value in the equity of QIAGEN N.V. as paid-in capital.

In October 2012, we completed a private placement through the issuance of new senior unsecured notes at a total amount of $ 400 million with a weighted average interest rate of

3.66 % (settled on October 16, 2012). The notes were issued in three series: (1) $ 73 million 7-year term due in 2019

(3.19 %); (2) $ 300 million 10-year term due in 2022 (3.75 %); and (3) $ 27 million 12-year term due in 2024 (3.90 %). Ap- proximately €170 million (approximately $ 220 million) of proceeds from the notes were used to repay amounts out- standing under our short-term revolving credit facility. The remainder of the proceeds provides additional resources to support QIAGEN’s longer-term business expansion.

In 2012, our Supervisory Board approved a program au- thorizing management to purchase up to a total of $ 100 mil- lion of our common shares (excluding transaction costs). In the first half of 2013, 3.1 million QIAGEN shares were re- purchased for approximately $ 63.3 million. We completed the share repurchase program in April 2013 having repur- chased between October 2012 and April 2013 a total of

5.1 million QIAGEN shares for a total aggregate cost of $ 99.0 million.

In July 2013, we announced our intention to exercise the autho- rization granted by the Annual General Meeting of Share- holders on June 26, 2013, to purchase up to $ 100 million of our common shares (excluding transaction costs) in a second share repurchase program. Based on the closing price on July 29, 2013, this represents approximately 5.0 million com- mon shares. Repurchased shares will be held in treasury in

order to satisfy obligations for exchangeable debt instru- ments and employee share-based remuneration plans. In 2013,

1.0 million QIAGEN shares were repurchased for $ 22.7 mil- lion under this program.

We expect that cash from financing activities will continue to be impacted by issuances of our common shares in connection with our equity compensation plans and that the market perfor- mance of our stock will impact the timing and volume of the issuances. Additionally, we may make future acquisitions or investments requiring cash payments, the issuance of addi- tional equity or debt financing.

We believe that funds from operations, existing cash and cash equivalents, together with the proceeds from our public and private sales of equity, and availability of financing facil- ities, will be sufficient to fund our planned operations and expansion during the coming year. However, the global eco- nomic downturn may have a greater impact on our business than currently expected, and we may experience a decrease in the sales of our products, which could impact our ability to generate cash. The availability of debt financing has also been negatively impacted by the global credit crisis. If our future cash flows from operations and other capital re- sources are not adequate to fund our liquidity needs, we may be required to obtain additional debt or equity financing or to reduce or delay our capital expenditures, acquisitions or research and development projects. If we could not obtain financing on a timely basis or at satisfactory terms, or imple- ment timely reductions in our expenditures, our business could be adversely affected.